Objective: To determine if goserelin immediately after uterine artery embolization (UAE) affected myoma reduction. Design: Randomized pilot study (level 1). Setting: Teaching hospital. Patient(s): Twenty-six women. Intervention(s): All patients underwent UAE, and then 12 patients received 10.8 mg of goserelin 24 hours later. The treatment group was 5 years older: 43 versus 37.7 years. Uterine and myoma volumes were measured by ultrasound 2 weeks before UAE and at 3, 6, and 12 months. Main Outcome Measure(s): Uterine and fibroid volumes. Result(s): Pretreatment uterine volume was 477 versus 556 cm3, and dominant fibroid volume was 257 versus 225 cm3 in the control versus goserelin groups. Analysis of variance measurements indicated that the change over time did not significantly differ between the two groups. By 12 months, the control group had a mean uterine volume reduction of 58% , while the goserelin group had a reduction of 45% . Dominant fibroid changes over time did not differ between the two groups. At 12 months, the mean fibroid volume had decreased by 86% and 58% in the control and goserelin groups, respectively. Conclusion(s): The addition of goserelin therapy to UAE did not alter the reduction rate or volume of uterine myomas. Objective: To determine if goserelin immediately after uterine artery embolization (UAE) affected myoma reduction. Design: Randomized pilot study (level 1). Setting: Teaching hospital. Patient (s): Twenty-six women. Intervention underwent UAE and 12 patients received 10.8 mg of goserelin 24 hours later. The treatment group was 5 years older: 43 versus 37.7 years. Uterine and myoma volumes were measured by ultrasound for 2 weeks before UAE and at 3, 6, and 12 months Results (s): Uterine and fibroid volumes. Result (s): Pretreatment uterine volume was 477 versus 556 cm3, and dominant fibroid volume was 257 versus 225 cm3 in the control versus goserelin groups. Analysis of variance measurements indicated that the By 12 months, the control group had a mean uterine volume reduction of 58% while while the goserelin group had a reduction of 45%. Dominant fibroid changes over time did not differ be tween the two groups. At 12 months, the mean fibroid volume had decreased decreased 86% and 58% in the control and goserelin groups, respectively. Conclusion (s): The addition of goserelin therapy to UAE did not alter the reduction rate or volume of uterine myomas.